Iambic Therapeutics has introduced Enchant, a powerful AI model designed to predict drug properties and improve clinical success rates from early discovery stages, aiming to cut costs, reduce risks and accelerate drug development. (Source: Image by RR)

Multi-Modal Enchant Transformer Predicts Drug Properties with Unmatched Accuracy

Iambic Therapeutics, a biotechnology company specializing in AI-driven drug discovery, has launched Enchant™, a multi-modal transformer model designed to provide predictive insights into clinical properties of potential drugs from the earliest stages of research. Enchant enables Iambic’s scientists to make early predictions on pharmacokinetic (PK) properties, such as how the body interacts with drugs, which can help reduce the risk of failure in clinical trials, lower drug development costs, and decrease the burden on trial participants by identifying promising candidates sooner.

As noted in iambic.ai, Enchant is unique in its ability to process diverse data types simultaneously, utilizing a mix of public and private data to predict critical drug properties that influence clinical success. By combining minimal human trial data with preclinical discovery data, Enchant enables researchers to anticipate how molecules might behave in humans before clinical testing begins, a process that could shorten drug development timelines and prevent late-stage failures, as highlighted by CEO Tom Miller and MIT’s Associate Professor Connor Coley.

In a recent white paper, Iambic demonstrated Enchant’s predictive power, showing that even with limited data, the model achieves strong predictive performance that improves with more preclinical data. Trained on the full Obach human PK dataset, Enchant achieved a Spearman correlation coefficient of 0.74 for predicting human PK half-life, a significant improvement over the prior state-of-the-art of 0.58, and outperformed other models across a range of laboratory and clinical tasks. This predictive accuracy could streamline drug development by supplementing scarce clinical data with more abundant preclinical data.

As a fully multi-modal transformer, Enchant addresses key data challenges in drug discovery by standardizing diverse data types and improving model training efficiency. Founded in 2019, Iambic Therapeutics is based in San Diego, California, and focuses on accelerating drug development through its AI-powered platform. With Enchant, Iambic aims to deliver high-quality therapeutics more rapidly, advancing its pipeline to meet urgent patient needs and establish itself as a leader in AI-driven drug discovery.

read more at iambic.ai